Trial Profile
A phase III multicentre, randomized open-label study of Revlimid (lenalidomide) plus dexamethasone (ReDex) versus observation in patients with smoldering multiple myeloma (MM) at high risk of progression to symptomatic MM
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Sep 2022
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary) ; Lenalidomide (Primary)
- Indications Smoldering multiple myeloma
- Focus Registrational; Therapeutic Use
- Acronyms QUIREDEX
- 03 Sep 2022 Results of an analysis assessesd Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time published in the European Journal of Cancer
- 21 Jun 2020 Results of 10 year follow up, presented at the 25th Congress of the European Haematology Association.
- 26 Sep 2018 This trial has been discontinued in Spain.